{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:08:26Z","timestamp":1774969706010,"version":"3.50.1"},"reference-count":14,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,25]]},"DOI":"10.1182\/bloodadvances.2024014889","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T19:53:13Z","timestamp":1735588393000},"page":"950-953","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-8042","authenticated-orcid":false,"given":"Samer","family":"Al Hadidi","sequence":"first","affiliation":[{"name":"1Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7487-9095","authenticated-orcid":false,"given":"Obada","family":"Ababneh","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-1741","authenticated-orcid":false,"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[{"name":"1Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[{"name":"1Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clyde","family":"Bailey","sequence":"additional","affiliation":[{"name":"1Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Smith","sequence":"additional","affiliation":[{"name":"1Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Panozzo","sequence":"additional","affiliation":[{"name":"1Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisy","family":"Alapat","sequence":"additional","affiliation":[{"name":"3Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3111-9739","authenticated-orcid":false,"given":"Guido","family":"Tricot","sequence":"additional","affiliation":[{"name":"1Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"John","family":"Shaughnessy","sequence":"additional","affiliation":[{"name":"1Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-2973","authenticated-orcid":false,"given":"Fenghuang","family":"Zhan","sequence":"additional","affiliation":[{"name":"1Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Sawyer","sequence":"additional","affiliation":[{"name":"1Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9824-6612","authenticated-orcid":false,"given":"Eric R.","family":"Siegel","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[{"name":"1Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[{"name":"1Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[{"name":"1Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"20","key":"2025032418280953300_bib1","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","article-title":"Curing myeloma at last: defining criteria and providing the evidence","volume":"124","author":"Barlogie","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2025032418280953300_bib2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","article-title":"Long-term outcomes after autologous stem cell transplantation for multiple myeloma","volume":"4","author":"Nishimura","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2025032418280953300_bib3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/bloodadvances.2023011601","article-title":"Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up","volume":"8","author":"Al Hadidi","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"2025032418280953300_bib4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/oncolo\/oyad306","article-title":"Perspectives on the treatment of multiple myeloma","volume":"29","author":"Rafae","year":"2023","journal-title":"Oncol"},{"issue":"9","key":"2025032418280953300_bib5","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jtct.2022.06.013","article-title":"High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma","volume":"28","author":"Ali","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2025032418280953300_bib6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.hoc.2023.12.005","article-title":"Is there still a role for stem cell transplantation in multiple\u00a0myeloma?","volume":"38","author":"Gertz","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"2025032418280953300_bib7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jha2.680","article-title":"Follow up duration of phase III multiple myeloma clinical trials: a systematic review","volume":"4","author":"Ali","year":"2023","journal-title":"EJHaem"},{"issue":"2","key":"2025032418280953300_bib8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2006.06271.x","article-title":"Long-term outcome results of the first tandem autotransplant trial for multiple myeloma","volume":"135","author":"Barlogie","year":"2006","journal-title":"Br J Haematol"},{"issue":"10","key":"2025032418280953300_bib9","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025032418280953300_bib10","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3","volume":"138","author":"Barlogie","year":"2007","journal-title":"Br J Haematol"},{"issue":"21","key":"2025032418280953300_bib11","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","article-title":"Superior results of total therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance","volume":"115","author":"Nair","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2025032418280953300_bib12","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1158\/1078-0432.CCR-15-2620","article-title":"Adverse metaphase cytogenetics can be overcome by adding bortezomib and thalidomide to fractionated melphalan transplants","volume":"23","author":"Jethava","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"25","key":"2025032418280953300_bib13","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2025032418280953300_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/950\/2356795\/blooda_adv-2024-014889-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/950\/2356795\/blooda_adv-2024-014889-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T21:07:31Z","timestamp":1742850451000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/4\/950\/534872\/Long-term-follow-up-of-Total-Therapy-IV-a-phase-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,2,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014889","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]}}}